Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Clinical trial NCT01658501 · COMPLETED
Trial details
- NCT number
- NCT01658501
- Sponsor
- PhaseBio Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-01
- Primary completion
- 2013-07-01
- Enrollment
- 593
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.